IL10 and listeriosis: Since patients with listeriosis have failed to produce anti-LLO antibodies [9], we focused on GNP-GAPDH1-22 nanovaccines, selecting the adjuvant DIO-1 for the vaccine formulation, because it induces IL-12p40 and fails to produce IL-10 [40], avoiding disproportionate inflammation in the brain.